Back

Therapeutic value of spironolactone in wild-type transthyretin amyloid cardiomyopathy

11 May 2024 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease 1 Clinical HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Luisa Pinheiro

Unidade Local de Saude do Alto Ave, Guimaraes (Portugal)

5 More presentations in this session

Presentation thumbnail
SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?
Doctor L. Pinheiro (Guimaraes, PT)
Abstract Slides Video
Presentation thumbnail
Stabilizers of transthyretin in amyloid cardiomyopathy: a systematic review and meta-analysis.
Ms L. Burgos (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Improving survival rates of patients with light-chain cardiac amyloidosis in recent years
Doctor T. Nabeta (Sagamihara, JP)
Abstract Slides Video
Presentation thumbnail
Incidence and progression of left ventricular involvement in patients with arrythmogenic cardiomyopathy
Doctor A. Diaz Exposito (Malaga, ES)
Abstract Slides Video
Presentation thumbnail
Left ventricular non compaction in sub-saharan african adults
Doctor N. GAYE (Dakar, SN)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in myocardial disease 1

The Event

Event poster

Heart Failure 2024

11 May - 14 May 2024
You may be interested in
thumbnail
Congress Presentation
Neurohormonal therapies at baseline and follow-up and survival in patients with wild-type transthyretin cardiac amyloidosis
thumbnail
Congress Presentation
SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?
thumbnail
Congress Presentation
Cardiac resynchronization therapy, remodeling and outcome in patients with amyloid transthyretin cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources